NasdaqGM:CRSPBiotechs
CRISPR Therapeutics Expands Pipeline As CASGEVY Grows And Cash Pile Rises
CRISPR Therapeutics (NasdaqGM:CRSP) has expanded its lead CAR-T program, zugo-cel, into new autoimmune disease indications.
The company advanced multiple in vivo liver-directed gene editing and siRNA programs into clinical development.
CASGEVY, its gene-editing therapy, continues to see commercial traction, and a recent regulatory filing aims to extend its label to younger pediatric patients.
A major convertible notes offering has strengthened the balance sheet and is funding a broader...